[Ip-health] Supreme Court ruled in supportive of drug price regulations in olanzapine patent case

Heesob Nam hurips at gmail.com
Thu Dec 17 04:33:18 PST 2020

I'm glad to share this story.

The Supreme Court of Korea found that generic companies are not liable
for the drug price reduction triggered by generic entry when the price
reduction is made by the government's discretionary measures under the
drug price policy. This is comparable to the decision of Japanese
court (https://clarivate.com/darts-ip/blog/blog-featured-author-japan/).
And in many jurisdictions, generic companies have been held liable for
the price erosion.

Last year, five CSOs including Knowledge Commune and two experts, Dr.
Ruth Lopert and Prof. Brook Baker filed to the Supreme Court a written
submission, and the Court ruled as we claimed.

For details, http://knowledgecommune.net/index.php/2020/12/17/the-supreme-court-ruled-in-favor-of-public-health-policy-in-olanzapine-patent-dispute/

Heesob Nam, PhD

Representative and chief researcher, Knowledge Commune
Director, Commons Foundation
H: knowledgecommune.net (English) | ko.knowledgecommune.net (Korean)
T: +82 (0)2 796 1839
M: +82 (0)10 3925 2797
hurips at gmail.com, heesobnam at commons.foundation

More information about the Ip-health mailing list